SCHEMBL6691029

SCHEMBL6691029

CC(C)(C)OC(=O)C1CN(Cc2ccc(Oc3ccc(F)cc3)cc2)C(=O)N1C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
MMP2 P08253 2/20 0.41
MMP13 P45452 2/20 0.41
MMP1 P03956 1/20 0.41
MMP3 P08254 1/20 0.41
MMP9 P14780 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ACE P12821 3/20 0.41
HTT P42858 1/20 0.40
FKBP1A P62942 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
P2RX7 Q99572 1/20 0.39
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
CASP1 P29466 1/20 0.38
S1PR5 Q9H228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28968201 0.80 HPGD (0.43) ACEFKBP1ACASP1
SCHEMBL3631453 0.79 ACE (0.49) ALDH1A1TSHRMAPK1ACEFKBP1A
SCHEMBL30428928 0.77 HPGD (0.43) MAPK1HTTFKBP1ACASP1
SCHEMBL4435031 0.76 ACE (0.61) TDP1ACEFKBP1ACACNA1GCACNA1H
SCHEMBL7270216 0.76 ACE (0.61) TDP1ACEFKBP1ACACNA1GCACNA1H
SCHEMBL15122638 0.73 HPGD (0.45) TDP1FKBP1A
SCHEMBL15122636 0.73 HPGD (0.45) TDP1FKBP1A
SCHEMBL4566807 0.73 HPGD (0.39) MAPK1FKBP1ACASP1
SCHEMBL6692001 0.72 MMP13 (0.68) MMP2MMP13MMP1MMP3MMP9
SCHEMBL1292041 0.72 HPGD (0.46) TDP1ACEFKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1134215-B1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases PFIZER PROD INC (US) 2004-10-06 EP disclosed
US-20020147224-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases ROBINSON RALPH P (US) 2002-10-10 US disclosed
US-6458822-B2 (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES PFIZER INC. 2002-10-01 US disclosed
US-20010041710-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases PFIZER PRODUCTS INC. 2001-11-15 US disclosed
EP-1134215-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases Pfizer Products Inc. (US) 2001-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147224-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases MMP1, MMP8, MMP13 TDP1 523/4885MMP2 9/4885MMP13 3/4885
US-20010041710-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases MMP1, MMP8, MMP13 TDP1 523/4885MMP2 9/4885MMP13 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.